The Bundibugyo ebolavirus outbreak in Africa has raised global concern, especially as cases affect the Democratic Republic of Congo and neighbouring Uganda. With no licensed vaccine currently available for this Ebola strain, global health organisations are moving quickly to support vaccine development.
In a major step, Serum Institute of India (SII) has stepped up to manufacture an experimental Oxford Ebola vaccine. This move is backed by US$ 8.6 million in CEPI funding.
Also Read: ASUS AI Healthcare Ecosystem Unveiled at Computex 2026 with DuoScan & VivoWatch 6 Plus
Why This Vaccine Matters?
The Bundibugyo strain is one of the serious forms of Ebola virus disease. At present, there is no approved vaccine for this strain, making the development of new vaccine candidates urgent.
The Oxford vaccine candidate is based on the ChAdOx1 platform, the same technology used in the Oxford-AstraZeneca COVID-19 vaccine.
Three organizations are playing an important role in developing a vaccine against the current Bundibugyo Ebola outbreak:
- Oxford University has developed a new Ebola vaccine.
- Serum Institute of India will manufacture the vaccine.
- CEPI is funding and supporting the project.
To stop the Ebola outbreak in the DRC and Uganda, CEPI is helping speed up the development of three new vaccines. These vaccines are being made by IAVI, Moderna, and Oxford University. CEPI has provided $61.8 million in funding, and the Serum Institute of India will manufacture the Oxford vaccine.
The Alarming Gap This Vaccine Is Trying to Fill
Right now, the situation is alarming. There are no licensed vaccines available for the Bundibugyo strain of Ebola. There are also no candidates in clinical development, according to CEPI.
This makes the SII Oxford vaccine one of the most urgent medical projects in the world today.
The Oxford vaccine candidate is based on the ChAdOx1 platform — the same technology that powered the Oxford-AstraZeneca COVID-19 vaccine. This platform has already proven its worth globally.
Also Read: Urban India Records Moderate Wellbeing Score of 65, ManipalCigna IHQ 2026 Finds
From Funding to Vaccine — The $8.6 Million Roadmap
- CEPI has provided up to $8.6 million to support the Oxford Ebola vaccine project. The funding will help manufacture clinical-grade vaccine doses at SII's facilities in Pune, India. It will also support the creation of a Master Virus Seed stock. In addition, the funding will help prepare for Phase 1 human clinical trials.Here's a quick breakdown of what the money will support:
- Manufacturing of clinical trial doses at SII's Pune facility
- Creation of a Master Virus Seed stock
- Preclinical testing and early-stage development
- Preparation for Phase 1 human trials
The funding will also cover development activities for a ChAdOx1-derived Bundibugyo shot, alongside manufacturing for clinical trials.
Also Read: No Ebola Case in India Yet: Bengaluru Traveller Isolated as Precaution, DGCA Issues Advisory
Leaders Speak Out — The Urgency Is Real
Several experts have stressed the urgent need for an Ebola vaccine as the Bundibugyo virus continues to spread.
Richard Hatchett (CEPI CEO) said urgent action is needed because there is no approved vaccine for the Bundibugyo Ebola virus.
Adar Poonawalla (SII CEO) said SII will speed up vaccine production and ensure affordable access if the vaccine succeeds.
Professor Teresa Lambe (Oxford Vaccine Group) said global partners are working together to help control the outbreak.
Dr. Tedros Adhanom Ghebreyesus (WHO Director-General) described CEPI's support for three vaccine candidates as a major step in fighting the disease.
Also Read: Measles Outbreak 2026: Bangladesh Reports 528 Child Deaths as Global Health Crisis Worsens!
Serum Institute of India — Proven, Trusted, Ready
The Serum Institute of India (SII) is the world's largest vaccine maker and supplies vaccines to over 170 countries. It is known for responding quickly during disease outbreaks. In 2022, SII delivered an experimental Ebola vaccine to Uganda within just 80 days during an outbreak. Now, SII is using its experience to speed up the development of a vaccine against the Bundibugyo Ebola virus. SII is also part of CEPI's global vaccine manufacturing network.
The Bigger Picture — A $60 Million+ Mission
This project is part of a global program worth more than $60 million.
Its goal is to speed up the development of three experimental vaccines against the deadly Bundibugyo Ebola virus.
Source: CEPI official press release
Also Read: Canada Confirms First Andes Hantavirus Case Linked to Cruise Ship Outbreak; Public Risk Remains Low
The Path Forward — Trials, Testing and Hope
The road ahead is focused and urgent. The goal is to move fast — from manufacturing to clinical trials as quickly as possible.
CEPI has supported the development of over 30 vaccine candidates against its priority pathogens, including Ebola Virus Disease, Lassa virus, Nipah virus, and SARS-CoV-2.
The SII Oxford Ebola vaccine will go through preclinical testing first. If all goes well, Phase 1 trials on humans will begin soon after. The goal is to get a safe and effective Bundibugyo ebolavirus vaccine to affected countries — especially in Africa — as fast as possible.
Wrapping Up
The Serum Institute of India is once again proving its worth on the world stage. With CEPI's $8.6 million funding and Oxford's ChAdOx1 platform, there is real hope for millions of people at risk.
The Bundibugyo ebolavirus outbreak is deadly. But the global response is fast, well-funded, and united. The Oxford Ebola vaccine manufactured by SII could become a key tool in stopping this outbreak.
The world is watching — and India is leading the charge.
For more updates on Current Updates in India and Health News Today India, stay connected with News4Bharat for the latest developments, expert insights, and breaking stories from across the country.